Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040105 · ClinicalTrials.gov registry record · Phase 1
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00040105: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00040105 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040105, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of the drugs ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this combination on the leukemia will also be studied.
Interventions
- DRUG Zarnestra (R115777)
- DRUG Gleevec (Imatinib mesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2002-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040105
The ClinicalTrials.gov registry entry for NCT00040105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zarnestra (R115777) is the first listed.
NCT00040105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040105 about?
NCT00040105 is a clinical study titled "Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia". The goal of this clinical research study is to find the highest safe dose of the drugs ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this combination on the leukemia will ...
What is the current status of trial NCT00040105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2002-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00040105?
The interventions under investigation include: Zarnestra (R115777) (DRUG), Gleevec (Imatinib mesylate) (DRUG).
Who is sponsoring clinical trial NCT00040105?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.